Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II tucidinostat monotherapy study in relapsed or refractory peripheral T-cell lymphoma
jRCTs061220060Phase 2Active, not recruiting
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in peripheral T-cell lymphoma (PTCL), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoint: Overall response rate. Started Oct 2022; status: active, not recruiting.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on jRCTs061220060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061220060.